Treatment with atezolizumab resulted in a statistically significant and clinically relevant improvement in overall survival.
Treatment with a full-dose regimen consisting of an anthracycline plus ifosfamide administered for 3 courses prior to surgery improves relapse-free and overall survival.
First-line treatment with nivolumab was not superior to investigator's choice of platinum-based doublet chemotherapy for progression-free survival.
Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.
Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.
Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.
Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer.
Study findings suggest that anti-PD1 immunotherapy may have significant activity among patients with early stage NSCLC.
A 1-day, 3-drug, fosaprepitant-containing regimen is efficacious for preventing chemotherapy-induced nausea and vomiting.
PD-L1 inhibition with durvalumab is associated with encouraging overall survival rates in pretreated HNSCC.
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.
Further investigation is warranted to assess the activity of abiraterone among patients with low grade serous EOC.
Among women with HER2-negative breast cancer, treatment with abemaciclib reduced Ki67 levels more than anastrozole.
Aurora kinase A inhibition with alisertib monotherapy may benefit a subset of patients with neuroendocrine prostate cancer (NEPC).
Vandetanib demonstrates antitumor activity among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC).
Ceritinib induced robust whole body responses in anaplastic lymphoma kinase (ALK) inhibitor-naive patients with ALK-rearranged non-small cell lung cancer (NSCLC).
Among patients with advanced soft tissue sarcoma, adding evofosfamide to doxorubicin failed to improve overall survival compared with doxorubicin alone.
Compared with best supportive care, trabectedin significantly improves progression-free survival among patients with pretreated advanced soft tissue sarcoma.
Everolimus plus letrozole is efficacious as a first-line treatment regimen for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
Second-line treatment with nivolumab was well tolerated and associated with encouraging preliminary activity among patients with hepatocellular carcinoma.
Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment.
In contrast with a 3 mg/kg dose, ipilimumab monotherapy at a dose of 10 mg/kg is associated with improved overall survival.
MYL-1401H is equivalent in efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia among patients with breast cancer.
Lurbinectedin induces DNA double-strand breaks, and regulates the tumor microenvironment.
Adding chemoradiotherapy prior to surgery improves survival versus surgery alone in patients with locally advanced esophageal squamous cell carcinoma (SCC).
Researchers can use metastasis-free survival as a surrogate end point for overall survival in clinical trials evaluating patients with localized prostate cancer.
Treatment with selinexor is active in patients with heavily pretreated patients with metastatic ovarian or endometrial cancer.
Prexasertib demonstrates promising activity in patients with BRCA wild type sporadic high-grade serous ovarian cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?